Physician profile
Michael Montella
NPI 1881674802
$11,488.92
in general payments reported to CMS, 2019-2025
33 companies · $2,075 in 2025
The $2,075 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,617 · 2020: $964 · 2021: $1,362 · 2022: $1,485 · 2023: $1,851 · 2024: $2,136 · 2025: $2,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,018 · Education: $42.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,018.32 |
| Education | $42.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,190.11 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $1,484.37 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,131.08 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $1,036.12 | 2019-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $982.88 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Lilly USA, LLC | $736.10 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $720.63 | 2021-2025 | |
| Pfizer INC. | $617.36 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $359.21 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $229.57 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $210.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $206.17 | 2019-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $162.90 | 2019-2025 | |
| Abbott Laboratories | $151.17 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $150.08 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $148.24 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $116.84 | 2019-2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.42 | 2019-2024 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $99.14 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $96.82 | 2019-2024 | Xarelto |
| Sumitomo Pharma America, INC. | $91.76 | 2023-2024 | Gemtesa |
| Esperion Therapeutics, INC. | $89.81 | 2020-2024 | Nexletol |
| Eisai INC. | $73.01 | 2022-2024 | |
| Dexcom, INC. | $70.64 | 2022-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $36.81 | 2025 | Voquezna |
| Allergan, INC. | $34.76 | 2019-2020 | |
| Almatica Pharma LLC | $31.12 | 2022-2023 | Gralise, Loreev Xr |
| Xeris Pharmaceuticals, INC. | $25.99 | 2022-2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $25.55 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $23.03 | 2019 | |
| Shire North American Group INC | $17.55 | 2019 | |
| Verona Pharma, INC. | $15.49 | 2025 | Ohtuvayre |
| Biohaven Pharmaceuticals, INC. | $13.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Montella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.